BioCentury
ARTICLE | Financial News

Follow-on roundup: Actinium, Kamada, Tetraphase

July 28, 2017 11:20 PM UTC

Immunotherapy play Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) and infectious disease company Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) each priced follow-on offerings, raising more than $96 million combined.

Actinium raised $16.1 million through the sale of 21.5 million shares at $0.75 in a follow-on underwritten by Oppenheimer, Maxim Group and Jones Trading Institutional Services. The price is a 23% discount to Actinium's close on Thursday when it proposed the offering after market hours. Investors also received five-year warrants to purchase 18.3 million shares at $1.05. Actinium fell $0.30 (31%) to $0.67 on Friday. Actinium's Iomab-B is in a Phase III trial to treat relapsed or refractory acute myelogenous leukemia (AML). The candidate is an anti-CD45 mAb (BC8) labeled with iodine-131...